ArticleFrontiers in medicine2025
Prevalence, clinical characteristics, and biological markers of postmenopausal osteoporosis and knee osteoarthritis in Beijing: study protocol for a cross-sectional and prospective study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Estrogen deficiency as a common driver and integrative mechanism in osteoporosis‑osteoarthritis comorbidity (Review).Molecular medicine reports · 2026Review
- Integrated Network Pharmacology and Proteomics Reveal That Erxian Decoction Counteracts Postmenopausal Osteoporosis via GSTA1-Mediated Oxidative Stress Suppression.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postmenopausal osteoporosis (PMOP) and knee osteoarthritis (KOA) are common musculoskeletal disorders that share risk factors such as aging, hormonal changes, and inflammation. PMOP often remains asymptomatic until fractures occur, while KOA leads to pain and disability. Their comorbidity remains underexplored, particularly in community settings. This study aims to investigate the prevalence, risk factors, and clinical features of PMOP-KOA comorbidity among Beijing residents aged 45-80 years, providing evidence-based recommendations for early identification, prevention, and management. Methods: Over 2 years, this study will conduct a PMOP-KOA screening and prospective follow-up in the Beijing community to investigate the incidence, risk factors, and clinical characteristics of PMOP-KOA. This study will undertake bone mineral density detection, collect biological samples, and record information via questionnaires. Discussion: The study aims to investigate the incidence, risk factors, and clinical characteristics of PMOP-KOA comorbidity and explore related traditional Chinese medicine syndromes based on large community-based samples in Beijing. Data on PMOP-KOA occurrence and associated risk factors over the 2 years follow-up will be available on the Chinese Clinical Trial Registry (ChiCTR2300073575).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.